TinyGemsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) to Host Investor Webinar on Feb. 5

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company advancing targeted antitumor virotherapies, will host an investor webinar on Feb. 5, 2025, at 4:15 p.m. ET. The event, organized by RedChip Companies, will feature CFO Andrew Jackson and CSO Antonio F. Santidrian, PharmD, PhD, discussing Calidi’s cell-based delivery platforms designed to enhance oncolytic virus-based cancer treatments. Topics will include the company’s lead programs, such as CLD-400 for metastatic cancers, CLD-201 for advanced solid tumors, and CLD-101 for high-grade glioma. A live Q&A session will follow.

To view the full press release, visit: https://ibn.fm/2fTQw

About Calidi Biotherapeutics

Calidi Biotherapeutics specializes in proprietary technology that empowers the immune system to combat cancer. The company’s novel stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi’s clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi’s preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California.

For more information, please visit www.calidibio.com

About TinyGems

TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN